
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
San Diego -- A new web-based teaching module addresses the 80-hour-work-week regulations to improve the dermatology knowledge base of pediatric residents. It could have broader applications, said Eliot Mostow, M.D., MPH.